These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35490565)

  • 1. Autologous dendritic cells pulsed with allogeneic tumour cell lysate induce tumour-reactive T-cell responses in patients with pancreatic cancer: A phase I study.
    Lau SP; Klaase L; Vink M; Dumas J; Bezemer K; van Krimpen A; van der Breggen R; Wismans LV; Doukas M; de Koning W; Stubbs AP; Mustafa DAM; Vroman H; Stadhouders R; Nunes JB; Stingl C; de Miranda NFCC; Luider TM; van der Burg SH; Aerts JG; van Eijck CHJ
    Eur J Cancer; 2022 Jul; 169():20-31. PubMed ID: 35490565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo induction of dendritic cell-mediated cytotoxicity against allogeneic pancreatic carcinoma cells.
    Stift A; Friedl J; Dubsky P; Bachleitner-Hofmann T; Benkoe T; Brostjan C; Jakesz R; Gnant M
    Int J Oncol; 2003 Mar; 22(3):651-6. PubMed ID: 12579320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and tumour-specific immunological responses of combined dendritic cell vaccination and anti-CD40 agonistic antibody treatment for patients with metastatic pancreatic cancer: protocol for a phase I, open-label, single-arm, dose-escalation study (REACtiVe-2 trial).
    Lau SP; van 't Land FR; van der Burg SH; Homs MYV; Lolkema MP; Aerts JGJV; van Eijck CHJ
    BMJ Open; 2022 Jun; 12(6):e060431. PubMed ID: 35710239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dendritic Cell-Based Immunotherapy in Patients With Resected Pancreatic Cancer.
    van 't Land FR; Willemsen M; Bezemer K; van der Burg SH; van den Bosch TPP; Doukas M; Fellah A; Kolijn PM; Langerak AW; Moskie M; van der Oost E; Rozendaal NEM; Baart SJ; Aerts JGJV; van Eijck CHJ
    J Clin Oncol; 2024 Sep; 42(26):3083-3093. PubMed ID: 38950309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autologous Dendritic Cells Pulsed with Allogeneic Tumor Cell Lysate in Mesothelioma: From Mouse to Human.
    Aerts JGJV; de Goeje PL; Cornelissen R; Kaijen-Lambers MEH; Bezemer K; van der Leest CH; Mahaweni NM; Kunert A; Eskens FALM; Waasdorp C; Braakman E; van der Holt B; Vulto AG; Hendriks RW; Hegmans JPJJ; Hoogsteden HC
    Clin Cancer Res; 2018 Feb; 24(4):766-776. PubMed ID: 29233904
    [No Abstract]   [Full Text] [Related]  

  • 6. Complementary vaccination protocol with dendritic cells pulsed with autologous tumour lysate in patients with resected stage III or IV melanoma: protocol for a phase II randomised trial (ACDC Adjuvant Trial).
    Ridolfi L; de Rosa F; Fiammenghi L; Petrini M; Granato AM; Ancarani V; Pancisi E; Soldati V; Cassan S; Bulgarelli J; Riccobon A; Gentili G; Nanni O; Framarini M; Tauceri F; Guidoboni M
    BMJ Open; 2018 Aug; 8(8):e021701. PubMed ID: 30082356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma.
    Sakai K; Shimodaira S; Maejima S; Udagawa N; Sano K; Higuchi Y; Koya T; Ochiai T; Koide M; Uehara S; Nakamura M; Sugiyama H; Yonemitsu Y; Okamoto M; Hongo K
    J Neurosurg; 2015 Oct; 123(4):989-97. PubMed ID: 26252465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pilot trial of autologous dendritic cells loaded with tumor lysate(s) from allogeneic tumor cell lines in patients with metastatic medullary thyroid carcinoma.
    Bachleitner-Hofmann T; Friedl J; Hassler M; Hayden H; Dubsky P; Sachet M; Rieder E; Pfragner R; Brostjan C; Riss S; Niederle B; Gnant M; Stift A
    Oncol Rep; 2009 Jun; 21(6):1585-92. PubMed ID: 19424640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside.
    Chiang CL; Kandalaft LE; Tanyi J; Hagemann AR; Motz GT; Svoronos N; Montone K; Mantia-Smaldone GM; Smith L; Nisenbaum HL; Levine BL; Kalos M; Czerniecki BJ; Torigian DA; Powell DJ; Mick R; Coukos G
    Clin Cancer Res; 2013 Sep; 19(17):4801-15. PubMed ID: 23838316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study.
    Pandha HS; John RJ; Hutchinson J; James N; Whelan M; Corbishley C; Dalgleish AG
    BJU Int; 2004 Aug; 94(3):412-8. PubMed ID: 15291878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy of autologous tumor lysate-loaded dendritic cell vaccines by a closed-flow electroporation system for solid tumors.
    Kamigaki T; Kaneko T; Naitoh K; Takahara M; Kondo T; Ibe H; Matsuda E; Maekawa R; Goto S
    Anticancer Res; 2013 Jul; 33(7):2971-6. PubMed ID: 23780988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity.
    Hong S; Li H; Qian J; Yang J; Lu Y; Yi Q
    Clin Exp Immunol; 2012 Nov; 170(2):167-77. PubMed ID: 23039887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autologous versus allogeneic peptide-pulsed dendritic cells for anti-tumour vaccination: expression of allogeneic MHC supports activation of antigen specific T cells, but impairs early naïve cytotoxic priming and anti-tumour therapy.
    Merrick A; Diaz RM; O'Donnell D; Selby P; Vile R; Melcher A
    Cancer Immunol Immunother; 2008 Jun; 57(6):897-906. PubMed ID: 18057935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase I Study of Autologous Dendritic Cell Vaccine Pulsed with Allogeneic Stem-like Cell Line Lysate in Patients with Newly Diagnosed or Recurrent Glioblastoma.
    Hu JL; Omofoye OA; Rudnick JD; Kim S; Tighiouart M; Phuphanich S; Wang H; Mazer M; Ganaway T; Chu RM; Patil CG; Black KL; Shiao SL; Wang R; Yu JS
    Clin Cancer Res; 2022 Feb; 28(4):689-696. PubMed ID: 34862245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma.
    Sarivalasis A; Boudousquié C; Balint K; Stevenson BJ; Gannon PO; Iancu EM; Rossier L; Martin Lluesma S; Mathevet P; Sempoux C; Coukos G; Dafni U; Harari A; Bassani-Sternberg M; Kandalaft LE
    J Transl Med; 2019 Nov; 17(1):391. PubMed ID: 31771601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma.
    Yu JS; Liu G; Ying H; Yong WH; Black KL; Wheeler CJ
    Cancer Res; 2004 Jul; 64(14):4973-9. PubMed ID: 15256471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines.
    Schnurr M; Galambos P; Scholz C; Then F; Dauer M; Endres S; Eigler A
    Cancer Res; 2001 Sep; 61(17):6445-50. PubMed ID: 11522639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients.
    Escobar A; López M; Serrano A; Ramirez M; Pérez C; Aguirre A; González R; Alfaro J; Larrondo M; Fodor M; Ferrada C; Salazar-Onfray F
    Clin Exp Immunol; 2005 Dec; 142(3):555-68. PubMed ID: 16297169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic partially HLA-matched dendritic cells pulsed with autologous tumor cell lysate as a vaccine in metastatic renal cell cancer: a clinical phase I/II study.
    Flörcken A; Kopp J; van Lessen A; Movassaghi K; Takvorian A; Jöhrens K; Möbs M; Schönemann C; Sawitzki B; Egerer K; Dörken B; Pezzutto A; Westermann J
    Hum Vaccin Immunother; 2013 Jun; 9(6):1217-27. PubMed ID: 23458999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.